Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis

Leukemia & Lymphoma
Pellegrino MustoAngelo Michele Carella

Abstract

Four cases of hypereosinophilic syndrome (HES) treated with the tyrosine-kinase inhibitor imatinib-mesylate are reported. The drug was effective in three patients, but a prolonged clinical and hematological remission was obtained only in one patient, due to appearance of resistance or poor tolerability in the other cases. The dose of imatinib necessary to achieve a response ranged from 100 to 600 mg/d. One patient with evidence of a clonal T-cell population did not respond at all. We confirm the efficacy of imatinib in HES, but we also underline that type and duration of response may be variable. This could be due to different pathogenetic mechanisms of the disease in single patients.

References

Jul 11, 2000·British Journal of Haematology·F RoufosseE Cogan
Mar 1, 2002·The New England Journal of Medicine·Hagop KantarjianUNKNOWN International STI571 CML Study Group
Jun 6, 2002·Lancet·Gerald J GleichJoseph H Butterfield
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Mar 28, 2003·The New England Journal of Medicine·Robert S Schwartz

❮ Previous
Next ❯

Citations

Jul 5, 2005·Acta Haematologica·A Tefferi
May 26, 2004·Leukemia Research·Pellegrino MustoGianfranco Catalano
Jul 12, 2012·Expert Review of Hematology·Elie Cogan, Florence Roufosse
Apr 13, 2006·European Journal of Haematology·Grzegorz HelbigJerzy Holowiecki
Jun 9, 2007·British Journal of Haematology·Claire E CurtisNicholas C P Cross
May 10, 2006·British Journal of Haematology·Ayalew TefferiAnimesh Pardanani
Jun 20, 2006·Best Practice & Research. Clinical Haematology·Jason GotlibD Gary Gilliland

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.